MMR News (1 article)
Novartis Tasigna® trial shows superior results to Glivec® in patients with early-stage chronic myeloid leukemia
. Tasigna surpassed Glivec in every measure of treatment efficacy designated in the trial including prevention of disease progression at 12 months . At 12-month milestone, significantly fewer patients progressed to accelerated or blastic phase on Tasigna 300 mg twice daily than on Glivec 400...
Published on 9 December 2009, 04:27
We have launched our peer- reviewed, Open-access journal: Insciences Journal